Cancer Mutation Improves Chemo Drug Performance

River D'Almeida, Ph.D
2 min readAug 19, 2020

When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcomes that take center stage. Take for example triple-negative breast cancer, a diagnostic marker for a condition that is notoriously difficult to treat and puts patients at significantly higher risks of relapse after therapy.

--

--

River D'Almeida, Ph.D

Follow me for bite-sized stories on the latest discoveries and innovations in biomedical research.